National assessment strategy for adults and children with a history of vaccine allergy shows low utility of COVID-19 vaccine skin testing

Article Immunology

Anaphylaxis: Revision of the Brighton collaboration case definition

Michael S. Gold et al.

Summary: The Brighton Collaboration (BC) has revised its case definition for anaphylaxis, which has been widely used in evaluating reports of suspected anaphylaxis following COVID-19 vaccination. This revision aligns the BC definition with other international case definitions and emphasizes the reporting of observable clinical signs. The BC definition is based on expert consensus and a literature review process.

VACCINE (2023)

Add to Collection

Letter Allergy

Second dose of COVID-19 vaccination in immediate reactions to the first BNT162b2

Jaime S. Rosa Duque et al.

PEDIATRIC ALLERGY AND IMMUNOLOGY (2022)

Add to Collection

Article Allergy

EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines

Milena Sokolowska et al.

Summary: The discussion focuses on the management and prevention of vaccine allergic reactions, providing a detailed algorithm for diagnosing and treating severe allergic reactions, along with recommendations for appropriate medications and equipment. A workup for identifying potential allergenic components in vaccines is proposed, along with a suggested international collaborative approach to reduce the risk of allergic reactions to COVID-19 vaccines.

ALLERGY (2021)

Add to Collection

Article Allergy

mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach

Aleena Banerji et al.

Summary: The FDA has authorized emergency use of Pfizer-BioNTech and Moderna COVID-19 vaccines, but individuals with severe allergic reactions are advised against receiving them. The CDC recommends observing those with a history of immediate allergies or anaphylaxis for 30 minutes post-vaccination, while all others should be observed for 15 minutes.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Add to Collection

Article Immunology

Evaluating Rates and Determinants of COVID-19 Vaccine Hesitancy for Adults and Children in the Singapore Population: Strengthening Our Community's Resilience against Threats from Emerging Infections (SOCRATEs) Cohort

Konstadina Griva et al.

Summary: The study found low rates of vaccine hesitancy for adults' own vaccination, but higher rates for children's vaccination. Factors influencing adult hesitancy included living with people in poor health, subjective norm, moral norm, benefits, and necessity of vaccination; while factors influencing parental hesitancy included male gender, lower perceived vaccine benefits, high COVID-19 risk perceptions, vaccination concerns, and necessity beliefs.

VACCINES (2021)

Add to Collection

Article Oncology

Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase

Catherine Mark et al.

Summary: Vaccination is crucial for preventing COVID-19 infection for both individuals and communities, however, some patients with acute lymphoblastic leukemia may develop allergic reactions to vaccines due to the medications they receive. Thus, it is essential to develop a safe vaccination plan for these patients.

PEDIATRIC BLOOD & CANCER (2021)

Add to Collection

Review Allergy

The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach

Matthew Greenhawt et al.

Summary: This study involved an international multidisciplinary group of experts to systematically investigate the incidence of anaphylaxis after SARS-CoV-2 vaccination and the accuracy of allergy testing tools. The research found a low incidence of anaphylaxis after SARS-CoV-2 vaccination and low sensitivity of polyethylene glycol skin testing, but high specificity. Recommendations were made for vaccination for individuals without a history of severe allergic reactions and shared decision-making with an allergy specialist for those with a history of severe allergic reactions. Further research is recommended to clarify the utility of testing in individuals potentially allergic to SARS-CoV-2 vaccines or their excipients.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Add to Collection

Article Allergy

First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing

Anna R. Wolfson et al.

Summary: Most patients with reported allergic reactions to the first dose of mRNA COVID-19 vaccines can safely receive the second dose after excipient skin testing, even if the results are positive. Some patients may require antihistamine medication or even epinephrine treatment.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Add to Collection

News Item Medicine, General & Internal

Covid-19: People with history of significant allergic reactions should not receive Pfizer vaccine, says regulator

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2020)

Add to Collection

Article Immunology

Anaphylaxis:: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data

Jens U. Rueggeberg et al.

VACCINE (2007)

Add to Collection

National assessment strategy for adults and children with a history of vaccine allergy shows low utility of COVID-19 vaccine skin testing

Related references

Export Citation

Share Paper